INCY Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.…
Industry Peers
BiotechnologyKey Statistics
About Incyte (NASDAQ: INCY)
›
Incyte (NASDAQ: INCY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,844 employees.
The shares were at 115.87 USD on 19 November 2026, up 9.3% over 52 weeks. Its 52-week range is 89.25 USD to 132.58 USD: the price is 12.6% below the high and 29.8% above the low.
At a market capitalisation of 23.62B USD, it trades at 59.1 times trailing earnings and 13.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 76% for INCY.
Incyte reports return on equity of 24.9%, an operating margin of 32.2% and revenue up 14.0% year over year.
It holds more cash than debt, a net cash position of 3.82B USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 24 analysts cover the stock, with an average rating of Buy; their mean price target of 132.17 USD is 14.1% above the current price. The next earnings report is expected on 9 February 2027.